← Back to Clinical Trials
Recruiting NCT05522972

NCT05522972 Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05522972
Status Recruiting
Phase
Sponsor Nova Southeastern University
Condition Amblyopia
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2022-09-13
Primary Completion 2029-08-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Video Game Vision TrainingPerceptual LearningOcclusion Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2022-09-13 with a primary completion date of 2029-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.

Eligibility Criteria

Inclusion Criteria: * adults and children with normal vision or amblyopia * amblyopia: interocular VA difference of 0.1 logMAR or more Exclusion Criteria: * any ocular pathological conditions, nystagmus

Contact & Investigator

Central Contact

Roger W Li, OD, PhD

✉ wli@nova.edu

📞 954-262-1436

Principal Investigator

Roger W Li, OD, PhD

PRINCIPAL INVESTIGATOR

Nova Southeastern University College of Optometry

Frequently Asked Questions

Who can join the NCT05522972 clinical trial?

This trial is open to participants of all sexes, studying Amblyopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05522972 currently recruiting?

Yes, NCT05522972 is actively recruiting participants. Contact the research team at wli@nova.edu for enrollment information.

Where is the NCT05522972 trial being conducted?

This trial is being conducted at Fort Lauderdale, United States.

Who is sponsoring the NCT05522972 clinical trial?

NCT05522972 is sponsored by Nova Southeastern University. The principal investigator is Roger W Li, OD, PhD at Nova Southeastern University College of Optometry. The trial plans to enroll 180 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology